Your browser doesn't support javascript.
loading
Cost-utility analysis of semaglutide for type 2 diabetes after its addition to the National Medical Insurance System in China.
Hu, Shanshan; Gu, Shengying; Qi, Chendong; Wang, Shuowen; Qian, Fengdan; Shi, Chenyang; Fan, Guorong.
Affiliation
  • Hu S; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Gu S; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Qi C; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Wang S; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Qian F; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shi C; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Fan G; Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Diabetes Obes Metab ; 25(2): 387-397, 2023 02.
Article de En | MEDLINE | ID: mdl-36193880
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 / Assurance Type d'étude: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Diabetes Obes Metab Sujet du journal: ENDOCRINOLOGIA / METABOLISMO Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 / Assurance Type d'étude: Health_economic_evaluation / Prognostic_studies Aspects: Patient_preference Limites: Humans Langue: En Journal: Diabetes Obes Metab Sujet du journal: ENDOCRINOLOGIA / METABOLISMO Année: 2023 Type de document: Article Pays d'affiliation: Chine Pays de publication: Royaume-Uni